In recent years, many diseases and symptoms have been found to have close connections with the microbiome, especially the gut microbiome group, which has been proven to deeply impact various diseases and symptoms in human beings. Under healthy conditions, the host cells and the vast diversity of microbes in microbiota can maintain a balance. Once microbiota dysbiosis occurs, many illnesses, such as metabolic syndromes, autoimmune diseases, cardiovascular problems, inflammatory bowel diseases, neuropsychiatric disorders, asthma, and cancers, will arise. Live biotherapeutics (LBPs) and probiotics can re-establish the necessary balance between the microbiome and its host in several pathologies. These new agents function by modulating and augmenting the microbiome for beneficial or therapeutic effects. Therefore, they are safer, more convenient, and more effective. The design and construction of engineered live biotherapeutics targeting a range of human clinical applications are rapidly evolving.
Rheumatoid arthritis is a systemic autoimmune disease marked by chronic joint inflammation, bone erosion, and cartilage degradation. RA can also harm internal organs like the lungs, heart, and kidneys. Recently, a lead investigator with decades of experience in arthritis clinical trials has discovered a direct connection between rheumatoid arthritis and unusual changes in the body’s microbiota. According to the scientist, he discovered a new bacteria that can stimulate the development of immune responses similar to those seen in rheumatoid arthritis as well as joint swelling in mice. He also found that people who have the disease have immune responses that are directed against this bacteria, suggesting that these bacteria could stimulate the production of these antibodies in humans. This new discovery is excellent news for those who have rheumatoid arthritis.
Live biotherapeutics represents a revolutionary method for the prevention and treatment of human diseases. Abundant of research for live biotherapeutics development is running. It should be noted that there are numerous stages involved in the development of live biotherapeutics, including strain identification and validation as well as analytical development and qualification, all of which are essential to the development of qualified live biotherapeutics. For example, the biology safety test for live biotherapeutics must be conducted to ensure that there is no potential safety hazard to the human body. As a life science company, Creative Biolabs aims to support researchers’ projects regarding live biotherapeutics development by providing innovative technologies, specific microbiological experts, and flexible methods for the analysis and identification clients require in the assay.
Although there is a long way to go, to sum up, some scientists stated that they believe that the microbiome will be the next evolution in medicine.